Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Comment by pabalooon Nov 19, 2020 3:40pm
164 Views
Post# 31934783

RE:RE:RE:RE:RE:RE:RE:RE:Strong Cash Position at exit 2020

RE:RE:RE:RE:RE:RE:RE:RE:Strong Cash Position at exit 2020Most of the information on here is very accurate except for a few disgruntled shareholders who hate the Mulls. It's easy to see why if there long term just trend the share price back a few years. The past bunch of miss managers have destroyed the wealth of this once high flyer. Mull junior is left to try to recover some of the losses. Think about this for a minute... you run a company that payed millions for a drug and the company you bought it from is bought out from a competitor. The competitor then withholds the drug from you and you can't market it. If you think Mulls is the bad guy think again. Bausch is playing dirty and they have billions to try and force a settlement. This much I know. Cipher didn't select a distribution partner because it would torpedo any deal Bausch would be willing to offer and there are deep discussions for a Trulance deal. If this goes as far as an outcome from the arbitration then all bets are off. Bausch will most definitely make there last offer prior to an outcome. Cipher is worth 3 bucks high end Bausch maybe willing to offer 2 high end this makes a 27 million dollar difference. If they offer a 10 to 1  Cipher shares for Bausch it puts us in the middle range. I'm guessing that's where we end up. As for the personalities running this company I don't care show me the money.
<< Previous
Bullboard Posts
Next >>